Emapalumab
Multi tool use
Emapalumab
Jump to navigation
Jump to search
| Monoclonal antibody | |
|---|---|
| Type | Whole antibody |
| Source | Human |
| Target | IFN-gamma |
| Clinical data | |
| Synonyms | NI-0501 |
| Routes of administration | IV, parenteral |
| ATC code |
|
| Identifiers | |
| CAS Number |
|
| ChemSpider |
|
| UNII |
|
| Chemical and physical data | |
| Formula | C6430H9898N1718O2038S46 |
| Molar mass | 154.4 g/mol |
Emapalumab (NI-0501)[1] is an experimental drug in development by Novimmune. It is an anti-IFNγ antibody for the treatment of hemophagocytic lymphohistiocytosis,[2] which currently has no cure.[3]
A phase II/III trial began in 2013 and is ongoing.[4] The trial targets patients under the age of 18 who have failed to improve on conventional treatments.[5]. This study was realised in the context of an EU-funded FP7 project, named FIGHT-HLH (306124)
The FDA awarded orphan drug status in 2012, and breakthrough therapy designation in 2016 on the basis of preliminary data from the phase II trial.[6][7]
References[edit]
^ https://searchusan.ama-assn.org/usan/documentDownload?uri=%2Funstructured%2Fbinary%2Fusan%2Femapalumab.pdf
^ https://www.novimmune.com/en/pipeline/ni-0501-anti-ifngamma.html
^ "Long-term Follow-up of HLH Patients Who Received Treatment With NI-0501, an Anti-interferon Gamma Monoclonal Antibody - Full Text View - ClinicalTrials.gov". clinicaltrials.gov..mw-parser-output cite.citationfont-style:inherit.mw-parser-output qquotes:"""""""'""'".mw-parser-output code.cs1-codecolor:inherit;background:inherit;border:inherit;padding:inherit.mw-parser-output .cs1-lock-free abackground:url("//upload.wikimedia.org/wikipedia/commons/thumb/6/65/Lock-green.svg/9px-Lock-green.svg.png")no-repeat;background-position:right .1em center.mw-parser-output .cs1-lock-limited a,.mw-parser-output .cs1-lock-registration abackground:url("//upload.wikimedia.org/wikipedia/commons/thumb/d/d6/Lock-gray-alt-2.svg/9px-Lock-gray-alt-2.svg.png")no-repeat;background-position:right .1em center.mw-parser-output .cs1-lock-subscription abackground:url("//upload.wikimedia.org/wikipedia/commons/thumb/a/aa/Lock-red-alt-2.svg/9px-Lock-red-alt-2.svg.png")no-repeat;background-position:right .1em center.mw-parser-output .cs1-subscription,.mw-parser-output .cs1-registrationcolor:#555.mw-parser-output .cs1-subscription span,.mw-parser-output .cs1-registration spanborder-bottom:1px dotted;cursor:help.mw-parser-output .cs1-hidden-errordisplay:none;font-size:100%.mw-parser-output .cs1-visible-errorfont-size:100%.mw-parser-output .cs1-subscription,.mw-parser-output .cs1-registration,.mw-parser-output .cs1-formatfont-size:95%.mw-parser-output .cs1-kern-left,.mw-parser-output .cs1-kern-wl-leftpadding-left:0.2em.mw-parser-output .cs1-kern-right,.mw-parser-output .cs1-kern-wl-rightpadding-right:0.2em
^ "A Study to Investigate the Safety and Efficacy of an Anti-IFNγ mAb in Children Affected by Primary Haemophagocytic Lymphohistiocytosis - Full Text View - ClinicalTrials.gov". clinicaltrials.gov.
^ "NI-0501: A Study to Investigate the Safety and Efficacy of an Anti-IFN? mAb in Children Affected by Primary Hemophagocytic Lymphohistiocytosis". www.cincinnatichildrens.org.
^ "Novimmune's NI-0501 Granted Breakthrough Therapy Designation by US FDA for Treatment of Patients With Primary Hemophagocytic Lymphohistiocytosis (HLH) - FierceBiotech". www.fiercebiotech.com.
^ "Emapalumab - NovImmune - AdisInsight". adisinsight.springer.com.
Categories:
- Drugs not assigned an ATC code
- Experimental drugs
- Monoclonal antibodies
- Orphan drugs
- Breakthrough therapy
(window.RLQ=window.RLQ||).push(function()mw.config.set("wgPageParseReport":"limitreport":"cputime":"0.388","walltime":"0.474","ppvisitednodes":"value":3616,"limit":1000000,"ppgeneratednodes":"value":0,"limit":1500000,"postexpandincludesize":"value":63728,"limit":2097152,"templateargumentsize":"value":1405,"limit":2097152,"expansiondepth":"value":14,"limit":40,"expensivefunctioncount":"value":1,"limit":500,"unstrip-depth":"value":1,"limit":20,"unstrip-size":"value":14004,"limit":5000000,"entityaccesscount":"value":1,"limit":400,"timingprofile":["100.00% 396.222 1 -total"," 72.52% 287.344 1 Template:Infobox_drug"," 49.06% 194.396 1 Template:Infobox"," 21.42% 84.884 1 Template:Reflist"," 18.60% 73.706 5 Template:Cite_web"," 15.19% 60.180 16 Template:Unbulleted_list"," 7.53% 29.847 1 Template:Infobox_drug/chemical_formula"," 5.86% 23.214 4 Template:Navbox"," 4.93% 19.518 1 Template:Monoclonals_for_immune_system"," 3.30% 13.065 1 Template:Infobox_drug/maintenance_categories"],"scribunto":"limitreport-timeusage":"value":"0.154","limit":"10.000","limitreport-memusage":"value":3094182,"limit":52428800,"cachereport":"origin":"mw1232","timestamp":"20181010192851","ttl":1900800,"transientcontent":false);mw.config.set("wgBackendResponseTime":77,"wgHostname":"mw1238"););Pnipme HSVhd33FJPi BogFX7Y GgHdDNnIprWm7,N7gYOb7ajnEBKD580,vtAyP8,vl2GdUwbTyIf2nTQa5UCqCazSjeH
Clash Royale CLAN TAG
